Marketing pharmacetical products with wide segment all over india.
Post: Produts Manager
~ Through the acquisition of InvaGen, Cipla gains scale in the US generics market with a strong manufacturing and R&D base, access to broad product portfolio and a strong customer base consisting of top wholesalers/retailers
~ Through the acquisition of Exelan, Cipla gains access to the government and institutional market in the US
Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain closing conditions, is valued at $550 million and will be an all cash transaction. The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.
The health survey and development committee ,chaired by Sir Joseph Bhore, an Indian Civil Servant , had in 1946 already recommended the establishment of a national medical centre which would concentrate on meeting the need for highly qualified manpower to look after the nation's expanding health care activities . The dreams of Nehru and Amrit Kaur and the recommendations of the Bhore Committee converged to create a proposal which found favor with the government of New Zealand. A generous grant from New Zealand under the Colombo Plan made it possible to lay the foundation stone of All India Institute of Medical Sciences (AIIMS) in 1952.The AIIMS was finally created in 1956, as an autonomous institution through an Act of Parliament ,to serve as a nucleus for nurturing excellence in all aspect of health care.
